Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price fell 22.7% during mid-day trading on Tuesday . The stock traded as low as C$0.08 and last traded at C$0.09. 2,202,367 shares were traded during trading, an increase of 353% from the average session volume of 486,589 shares. The stock had previously closed at C$0.11.
Hemostemix Stock Performance
The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07. The business has a 50 day moving average of C$0.10 and a 200-day moving average of C$0.14. The stock has a market cap of C$11.66 million, a PE ratio of -2.33 and a beta of 0.20.
Insider Buying and Selling
In other Hemostemix news, Director Peter Alan Lacey acquired 200,000 shares of the stock in a transaction dated Thursday, March 6th. The stock was acquired at an average price of C$0.15 per share, with a total value of C$30,000.00. 10.43% of the stock is currently owned by company insiders.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- Dividend Capture Strategy: What You Need to Know
- Amer Sports: The New ONON and DECK of Consumer Discretionary?
- Using the MarketBeat Stock Split Calculator
- BigBear.ai: Risky AI Stock or Defense Tech Opportunity?
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
